Efficacy of topical 5% imiquimod with cryotherapy versus intralesional meglumine antimoniate in the treatment of anthroponotic cutaneous leishmaniasis

Iranian Journal of Dermatology

Volumn 14, Issue 56, 2011, Pages 42-47

  Meymandi, Simin Shamsi ^a   Meymandi, Manzumeh Shamsi ^a   Zandi, Soodabeh ^a   Dabiri, Shahriar ^a   Aflatoonian, Mahin ^a  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cryotherapy; Cutaneous leishmaniasis; Imiquimod; Meglimine antimoniate

Indexed keywords

EID: 84859842417     PISSN: 0021082X     EISSN: 27170721     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Hepburn NC. Cutaneous leishmaniasis: an overiew. J Postgrad Med 2003; 49:50-4.
2. Murray HW. Kala - azar- progress against a neglected disease. N Engl J Med 2002; 22: 1793-1794.
3. Choi CM, Lerner EA. Leishmaniasis as an emerging infection. J Investing Dermatol Symp Proc 2001;6:175-182.
4. Hsia R. Leishmaniasis. Available at: http://www.emedicine.com/emerg/topic269.htm. Accessed on April 15, 2007.
5. Leishmaniasis. In: Tropical disease research progress 1995-96: Thirteenth programme report. Geneva, Switzerland: World Health Organization; 1997.
6. Dowlati Y. Cutaneous leishmaniasis: clinical aspect. Clin Dermatol 1996; 14: 425-431.
7. th edn. Philadelphia, PA: Elsevier Churchill Livingstone, 2005: 2428-2442.
8. th edn. London: Bailliere Tindall 1982:93-115.
9. Smith PAJ. Long incubation period in leishmaniasis. BMJ 1955; 2: 1143.
10. Blum J, Desjeux P, Schwartz E, Beck B, Hatz C. Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother 2004;53:158-166.
11. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006; 19:111-126.
12. Minodier PH, Parola PH. Cutaneous leishmaniasis treatment. Travel Med Infect Dis 2007;5:150-158.
13. Imbertson LM, Beaurline JM, Couture AM, Gibson SJ, Smith RM, Miller RL, et al. Cytokine induction in hairless mouse and rat skin after topical application on the immune response modification. J Invest Dermatol 1998;110:734-739.
14. Buates S, Matlashewski G. Treatment of experimental leishmaniasis with the Immunomodalutors imiquimod and S-28463: efficacy and mode of action. J Infect Dis 1999; 179: 1485-1494.
15. Beutner KR, Tyring SK, Trofatter KF Jr, Douglas JM Jr, Spruance S, Owens ML, et al. Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother 1998;42:789-794.
16. Arevalo I, Ward B, Miller R, Meng TC, Najar E, Alvarez E, et al. Successful treatment of drug - resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis 2001; 33: 1847-1851.
17. Miranda-Verástegui C, Llanos-Cuentas A, Arévalo I, Ward BJ, Matlashewski G. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru. Clin Infect Dis 2005; 40:1395-1403.
18. Sharifi I, Zarezadeh M, Fekri AR. Identification of cutaneous leishmaniasis species by immunoflurescence examination using monoclonal antibodies in Kerman and Rafsanjan cities, south - eastern Iran. Hamdard Med 2001: 44: 103-106.
19. Firooz A, Khamesipour A, Ghoorchi MH, Nassiri-Kashani M, Eskandari SE, Khatami A, et al. Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis. Arch Dermatol 2006; 142: 1575-1579.
20. Najarian DJ, English JC. Imiquimod Cream: A new multipurpose topical therapy for dermatology. P&T 2003; 28: 122-126.
21. Crawford R, Holmes D, Meymandi S. Comparative study of the efficacy of combined imiquimod 5% cream and intralesional meglumine antimoniate versus imiquimod 5% cream and intalesional meglumine antimoniate alone for the treatment of cutaneous leishmaniasis. J Am Acad Dermatol.2005; 52 (suppl 1): S118.